Proacta, a San Diego based biotechnology company, has announced FDA approval of investigational new drug (IND) application for PR610, a hypoxia-activated irreversible multi-kinase inhibitor, for the treatment of cancer. With the IND ...
Tags: investigational new drug, IND
Apexigen, a biopharmaceutical company, has announced the filing of investigational new drug (IND) application for APX001, also known as SSS07, by its partner 3SBio [SSRX] of Shenyang, China. With the IND approval, APX001/SSS07 will be ...
Tags: IND approval, clinical trials, autoimmune diseases, inflammatory diseases